Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RNAZ
RNAZ logo

RNAZ News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

RNAZ News

TransCode Appoints New Chair of Scientific Advisory Board

Apr 27 2026PRnewswire

TransCode Secures $20 Million Financing for Cancer Treatment

Apr 07 2026PRnewswire

TransCode Secures $20 Million Financing Agreement

Apr 07 2026Newsfilter

TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics

Mar 03 2026PRnewswire

TransCode Publishes Novel Tumor Immunotherapy Research

Feb 23 2026PRnewswire

TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment

Jan 06 2026PRnewswire

TransCode's TTX-MC138 Significantly Extends Survival in Glioblastoma Mouse Models

Jan 06 2026Newsfilter

TransCode Appoints Jack E. Stover to Board of Directors, Enhancing Leadership Experience

Dec 22 2025PRnewswire

RNAZ Events

04/30 17:30
Transcode Therapeutics Files to Sell 15.96M Shares of Common Stock
Transcode Therapeutics files to sell 15.96M shares of common stock for holders
04/27 08:10
TransCode Executes Research Agreement with Michigan State University
TransCode announced the execution of a sponsored research agreement with Michigan State University. The agreement is designed to accelerate development of TransCode's pipeline candidates from the laboratory into clinical development. Research conducted at MSU will also focus on evaluation of TransCode's lead therapeutic candidate, TTX-MC138, in combination withSeviprotimut-L for potential synergies and in combination with standard-of-care therapies. TransCode acquired Seviprotimut-L through its acquisition of the parent company of Polynoma.
04/27 08:10
TransCode Therapeutics Appoints Anna Moore as Chair of Scientific Advisory Board
TransCode Therapeutics appointed Anna Moore as Chair of its Scientific Advisory Board. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a co-founder of TransCode Therapeutics and expert in molecular imaging and RNA-targeted cancer therapeutics. Prior to joining MSU, she had a 26-year career at Massachusetts General Hospital and Harvard Medical School, where she served as Professor of Radiology and Director of the Molecular Imaging Laboratory.

RNAZ Monitor News

Transcode Therapeutics stock surges amid market decline

Feb 05 2026

Transcode Therapeutics Inc rises on market strength

Jan 06 2026

RNAZ Earnings Analysis

No Data

No Data

People Also Watch